|Bid||5.70 x 3000|
|Ask||5.77 x 1800|
|Day's Range||5.01 - 6.13|
|52 Week Range||2.62 - 16.38|
|Beta (3Y Monthly)||2.33|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 6, 2019 - Nov 11, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.75|
This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Sintx Technologies (NASDAQ: SINT ) shares ...
Adverum Biotechnologies (ADVM) announces data from one cohort of an early-stage study, evaluating its gene therapy candidate, ADVM-022, in patients with wet AMD.
Adverum Biotechnologies Inc (NASDAQ: ADVM ) shares were plunging Thursday following the presentation of data from its gene therapy trial at a conference. What Happened Adverum, a gene therapy company focusing ...
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 11.) Avedro Inc (NASDAQ: AVDR ) Catalyst Pharmaceuticals ...
-- Zero anti-VEGF rescue injections required after one-time intravitreal dose of ADVM-022 -- -- Sustained improvements in retinal anatomy -- -- Was safe and well tolerated --.
-- Podium presentation of 24-week data from first cohort of the OPTIC trial at Retina Society 2019 Annual Meeting on September 12, 2019 at 7:41 am BST -- -- Adverum to host.
MENLO PARK, Calif., Aug. 28, 2019 -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare.
Investors need to pay close attention to Adverum Biotechnologies (ADVM) stock based on the movements in the options market lately.
On Aytu BioScience's (AYTU) upcoming earnings call, investor focus will be on its diversified portfolio of medicines approved to treat ailments like low testosterone, insomnia and male infertility.
Adverum Biotechnologies (ADVM) delivered earnings and revenue surprises of 25.81% and -100.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
-- Phase 1 OPTIC trial: 24-week data from first cohort to be presented at Retina Society in September; 52-week data to be presented in 1H20 -- -- Dosing of second cohort.
Perrigo (PRGO) is focused on Consumer Self Care Americas segment. It remains to be seen if this benefits the company's results in the soon-to-be reported quarter.
Adverum Biotechnologies, Inc. (ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today made several key personnel announcements. Board member and co-founder Mitchell Finer, Ph.D. is retiring from Adverum’s Board of Directors to focus on his new industry role. In addition, Mehdi Gasmi, Ph.D. will retire from his position as president and chief scientific officer of Adverum, effective September 16, 2019, and will join Adverum’s Board of Directors at that time.
Adverum Biotechnologies (ADVM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MENLO PARK, Calif., July 25, 2019 -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular diseases, today.
Adverum Biotechnologies (ADVM) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Adverum Biotechnologies, Inc. (ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the appointments of Carol Hoang, Pharm.D., MBA, to the newly-created position of vice president, medical affairs, and James Shahbazian to the role of vice president, finance. “We are excited to have Carol and Jim join our team at Adverum and they both bring important sets of expertise as we expand our medical and financial teams,” said Leone Patterson, chief executive officer of Adverum Biotechnologies. At Adverum, she will establish and lead all medical affairs activities.